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Background: Clopidogrel and aspirin are antiplatelet agents that are recommended to reduce the risk of recurrent
stroke and other cardiovascular events. Combination therapy of clopidogrel and aspirin has been shown to increase
the risk of hemorrhage, but the effects of the drugs on laboratory parameters have not been well studied in
patients in routine clinical practice. Therefore, we evaluated and compared the effects of combination therapy with
clopidogrel plus aspirin and aspirin monotherapy on laboratory parameters using a clinical database.
Methods: We used data from the Clinical Data Warehouse of Nihon University School of Medicine obtained
between November 2004 and April 2011, to identify cohorts of new users (n = 159) of clopidogrel (75 mg/day)
plus aspirin (100 mg/day) and new users (n = 834) of aspirin alone (100 mg/day). We used a multivariable
regression model and regression adjustment with the propensity score to adjust for differences in baseline
covariates between settings, and compare the mean changes in serum levels of creatinine, aspartate
aminotransferase, alanine aminotransferase and hematological parameters, including hemoglobin level,
hematocrit, and white blood cell (WBC), red blood cell and platelet counts up to two months after the start of
study drug administration.
Results: After adjustment, the reduction of WBC count in clopidogrel plus aspirin users was significantly greater
than that in aspirin alone users. All other tests showed no statistically significant difference in the mean change
from baseline to during the exposure period between clopidogrel plus aspirin users and aspirin alone users. The
combination of clopidogrel and aspirin increased the risk of gastrointestinal bleeding compared with aspirin
alone, with a relative risk ranging from 2.06 (95% CI, 1.02 to 4.13; p = 0.043) for the multivariate model and 2.61
(95% CI, 1.18 to 5.80; p = 0.0184) for propensity adjustment.
Conclusion: Our findings suggested that hematological adverse effects may be greater with combination
therapy of clopidogrel plus aspirin than with aspirin monotherapy.
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Clopidogrel and aspirin are antiplatelet agents that are
recommended to reduce the risk of recurrent stroke and
other cardiovascular events [1,2]. Combination therapy,
typically with clopidogrel and aspirin, is commonly
used for the prevention of cardiovascular events, when
given for an appropriate indication and duration [3].* Correspondence: takahashi.yasuo@nihon-u.ac.jp
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reproduction in any medium, provided the orAspirin inhibits platelet cyclooxygenase by irreversible
acetylation, thereby preventing the formation of thromb-
oxane A2 which is a powerful stimulant of platelet ag-
gregation [4]. Clopidogrel, a thienopyridine, acts by
inhibiting adenosine receptors, which inhibits the early
step of platelet activation [5]. Thus, the effect of combin-
ing aspirin and clopidogrel is synergistic in preventing
platelet aggregation, and this combination may offer cer-
tain theoretical benefits over either agent alone. Some
clinical trials have investigated the efficacy of the com-
bination of clopidogrel and aspirin. The combinationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with myocardial infarction with or without ST-
segment elevation, and after angioplasty or stenting
[6-10]. On the other hand, in the MATCH trial, combin-
ation therapy with clopidogrel plus aspirin in patients
with a prior stroke or TIA showed no significant benefit
in reducing major vascular events compared with
clopidogrel alone [11]. The CHARISMA trial has shown
that the combination of clopidogrel and aspirin was
not significantly more effective than aspirin alone in
reducing the rate of myocardial infarction, stroke, or
death from cardiovascular causes [12]. Based on these
clinical findings, combination therapy with aspirin and
clopidogrel is recommended for treatment of acute cor-
onary syndromes and the prevention of coronary events
after placement of a stent as the most appropriate indi-
cations [1]. The nature of antiplatelet therapy involves
an inherent risk of bleeding complications. Although
this combination of antiplatelet agents has been demon-
strated to offer clinical benefits under certain conditions,
it does raise the risk of bleeding complications [13].
Thus, there is a consensus that dual antiplatelet therapy
involves the issue of bleeding risk. Although previous re-
ports have assessed the side effects of antiplatelet agents,
they usually focused on the adverse events of antiplatelet
agents [14,15], and few studies have focused on the ef-
fects of the drugs on laboratory parameters. Therefore,
we evaluated and compared the effects of combination
therapy with clopidogrel plus aspirin and aspirin mono-
therapy on laboratory parameters including creatinine,
aspartate aminotransferase (AST), and alanine amino-
transferase (ALT) levels and hematological parameters
including red blood cell (RBC) count, white blood cell
(WBC) count, platelet count, hemoglobin level and
hematocrit, which are typically used in clinical practice
for checking side effects of drugs.
Methods
Data source
We obtained the study data from electronic medical re-
cords stored in the Nihon University School of Medicine
(NUSM) Clinical Data Warehouse (CDW), which is a
centralized data repository that integrates separate data-
bases, including an order entry database and a laboratory
results database, from the hospital information systems
at three hospitals affiliated with NUSM, and is described
elsewhere [16]. The prescription database in the CDW
contains information from approximately 0.6 million pa-
tients, and prescribing data are linked longitudinally to
detailed clinical information such as patient demograph-
ics, diagnosis, and laboratory data. Several epidemio-
logical studies examining the effects of drugs on
laboratory parameters using NUSM’s CDW have been
published [17-20].Study population
The cohorts identified for the study included Japanese
patients aged over 20 years who had been newly treated
with clopidogrel (75 mg per day) plus aspirin (100 mg
per day) or aspirin alone (100 mg per day) between
November 2004 and April 2011 (detailed profile in-
cluded in Additional file 1). We excluded patients who
had received other antiplatelet drugs, anticoagulants or
thrombolytics during the study period. We also excluded
patients who had severe comorbid conditions: increased
risk of bleeding including diagnosis of severe hepatic in-
sufficiency, renal failure or current peptic ulceration, his-
tory of systemic bleeding, other history of bleeding
diathesis or coagulopathy, or a contraindication to as-
pirin or clopidogrel during the study period. Conse-
quently, we identified 159 new users of clopidogrel plus
aspirin and 834 new users of aspirin alone. The ethics
committee of Nihon University School of Medicine ap-
proved the study protocol.
Exposure and outcome
In this study, the index date was defined as the date of
first prescription of the study drugs. The baseline meas-
urement period (non-exposure period) was defined as
within six months before the index date in the
clopidogrel plus aspirin and aspirin alone cohorts. The
exposure period (outcome measurement period) was de-
fined as between two weeks and two months after the
start of treatment with clopidogrel plus aspirin or aspirin
alone to evaluate the short-term effect of the study
drugs. Blood test data (creatinine, AST, and ALT levels,
and hematological parameters including RBC count,
WBC count, platelet count, hemoglobin level and
hematocrit) were collected for each individual at the
date nearest the index date in the baseline period, and at
the date nearest two months after the start of treatment
in the exposure period. Consequently, the mean (95%
confidence interval (CI)) exposure of clopidogrel plus as-
pirin and aspirin alone users was 36.0 (33.8-38.2) days
and 36.7 (35.8-37.7) days, respectively. There was no sta-
tistically significant difference in mean exposure days be-
tween them. Information on bleeding episodes of
patients who were newly diagnosed with intracranial
hemorrhage or gastrointestinal (GI) bleeding in the ex-
posure period was collected.
Covariates
For each individual, information on patient demograph-
ics (age and sex), medical history, current medication,
and laboratory results was collected. Medical history in-
cluded information on cerebrovascular disease (ICD-10
codes, I60-I69), ischemic heart disease (I20-I25), other
heart disease (I30-I52), other peripheral vascular disease
(I73), liver disease (K70-K77), kidney disease (N00-N19),
Takahashi et al. Cardiovascular Diabetology 2013, 12:87 Page 3 of 7
http://www.cardiab.com/content/12/1/87gout (M10), thyroid gland disorders (E00-E07), hyperlip-
idemia (E78.0-E78.5), hypertension (I10), and diabetes
mellitus (E10-E14) that had been diagnosed prior to the
index date. We recorded current users of medication in-
cluding antihypertensive agents, steroids, lipid-lowering
drugs, insulin, oral antihyperglycemic agents, non-
steroidal anti-inflammatory drugs (NSAIDs), proton
pump inhibitors (PPIs), histamine2-receptor antagonists
(H2 blockers), other anti-peptic ulcer agents, immuno-
suppressive drugs, diuretics, and anti-arrhythmic drugs,
defined as patients who had received these agents in the
60 days preceding the index date.
Statistical analysis
All analyses were performed with SAS software, version
9.2 (SAS Institute, Cary, NC). All reported p-values are
two sided. A result was considered statistically signifi-
cant if the p value was less than 0.05. To compare differ-
ences in baseline characteristics, we used t-test for
continuous variables and chi-squared test for categorical
data. Also, we used t-test to compare the mean values of
laboratory parameters at baseline between clopidogrel
plus aspirin users and aspirin alone users. The general
linear model approach was performed to calculate
multivariate-adjusted values of blood test parameters
and to compare the adjusted least-squares means of
changes from the baseline value to the exposure value
between clopidogrel plus aspirin users and aspirin alone
users. To reduce bias by controlling for baseline covari-
ates between settings, two adjusted models are
presented. The first model had regression (covariance)
adjustment with the propensity score. This method is an
effective tool to reduce bias in nonrandomized studies
[21,22], and is described elsewhere [23]. In brief, the
propensity score for each subject was obtained by fitting
a logistic regression model that includes the predictor
variable (i.e., clopidogrel plus aspirin users or aspirin
alone users) as an outcome and all baseline covariates
including age, sex, comorbid diseases (cerebrovascular
disease, ischemic heart disease, other heart disease, liver
disease, kidney disease, gout, thyroid gland disorders,
hyperlipidemia, hypertension, and diabetes mellitus)
and previous drugs (including antihypertensive agents,
steroids, lipid-lowering drugs, oral antihyperglycemic
agents, NSAIDs, PPIs, H2 blockers, other anti-peptic
ulcer agents, immunosuppressive drugs, anti-arrhythmic
drugs and chemotherapeutic drugs), as listed in Table 1.
With the propensity score included in the general linear
model, we assessed and compared the adjusted least-
squares means of changes in laboratory parameters
during the exposure period from baseline between
clopidogrel plus aspirin users and aspirin alone users.
The second model adjusted for age, sex and the
remaining covariates, which were selected using abackward stepwise elimination method (p < 0.10). To es-
timate the relative risk of intracranial hemorrhage or GI
bleeding for clopidogrel plus aspirin users and aspirin
alone users, we used the odds ratio and 95% CI from lo-
gistic regression in which we controlled for covariates
using the two adjustment models described above.
Results
The study included 159 patients who had been newly
treated with clopidogrel plus aspirin and 834 patients
who had been newly treated with aspirin alone. Table 1
shows the baseline characteristics of the patients. In
clopidogrel plus aspirin users, the mean age was 64.6 years
and 20.1 percent were women. Aspirin alone users
were older and were more likely to be women than
clopidogrel plus aspirin users; the mean age was
68.3 years and 39.5 percent were women. More than
two-thirds of each cohort had ischemic heart disease,
hyperlipidemia or diabetes mellitus, suggesting raised
risk of cardiovascular disease. Clopidogrel plus aspirin
users were more likely to have ischemic heart disease
and hyperlipidemia, and were less likely to have cere-
brovascular disease, liver disease, and kidney disease
than aspirin alone users. In current medications, clopidogrel
plus aspirin users were more likely to utilize lipid-lowering
drugs than aspirin alone users. On the other hand, as-
pirin alone users were more likely to utilize calcium
channel blockers, thiazide diuretics, NSAIDs, H2
blockers, diuretics and anti-arrhythmic drugs. Table 2
shows the mean values in laboratory parameters at
baseline. The mean hemoglobin level in clopidogrel
plus aspirin users was higher than that in aspirin alone
users. None of the other tests showed any statistically
significant difference in mean values at baseline be-
tween clopidogrel plus aspirin users and aspirin alone
users. Because differences in baseline covariates, in-
cluding age, sex, comorbid diseases and current medi-
cation, between clopidogrel plus aspirin users and
aspirin alone users may create potential bias, we used a
multivariate regression model and regression adjust-
ment with propensity score to control for potential
confounding covariates in our observational study.
Table 3 shows the mean changes in WBC count dur-
ing the exposure period compared with the baseline
period. In clopidogrel plus aspirin users, the reduction
of WBC count was significantly greater than that in as-
pirin alone users before and after adjustment for covari-
ates. The mean changes in other laboratory parameters
were not significantly different in clopidogrel plus as-
pirin users in comparison to those in aspirin alone users
(data are included in Additional file 2). Table 4 shows
the prevalence of patients who had hemorrhagic events
during the exposure period. The rate of GI bleeding was
3.14 percent in clopidogrel plus aspirin users, as
Table 1 Baseline characteristics of study population
Characteristics Clopidogrel plus aspirin Aspirin alone p
(n = 159) (n = 834)
Age (years, mean ± SE) 64.6 ± 1.0 68.3 ± 0.4 0.0005
Women 32 (20.13%) 329 (39.45%) <0.0001
Medical history
Cerebrovascular disease 40 (25.16%) 375 (44.96%) <0.0001
Ischemic heart disease 140 (88.05%) 536 (64.27%) <0.0001
Liver disease 38 (23.9%) 369 (44.24%) <0.0001
Kidney disease 57 (35.85%) 378 (45.32%) 0.0273
Hypertension 107 (67.3%) 495 (59.35%) 0.0603
Diabetes mellitus 122 (76.73%) 606 (72.66%) 0.2879
Hyperlipidemia 147 (92.45%) 668 (80.10%) 0.0002
Current medication
Insulin 3 (1.89%) 60 (7.19%) 0.0119
Oral hypoglycemic drug 25 (15.72%) 106 (12.71%) 0.3035
Lipid-lowering drug 38 (23.9%) 144 (17.27%) 0.0476
Antihypertensive drug 51 (32.08%) 590 (70.74%) <0.0001
ARB 27 (16.98%) 199 (23.86%) 0.0579
ACEI 4 (2.52%) 49 (5.88%) 0.0841
Beta-blocker 7 (4.4%) 53 (6.35%) 0.3437
CCB 39 (24.53%) 524 (62.83%) <0.0001
Thiazide diuretic 9 (5.66%) 127 (15.23%) 0.0013
Other 14 (8.81%) 80 (9.59%) 0.756
NSAID 12 (7.55%) 191 (22.9%) <0.0001
Steroid 4 (2.52%) 82 (9.83%) 0.0026
H2 blocker 17 (10.69%) 455 (54.56%) <0.0001
Proton pump inhibitor 19 (11.95%) 151 (18.11%) 0.059
Antiepileptic drug 2 (1.26%) 55 (6.59%) 0.008
Immunosuppressive drug 0 (0%) 18 (2.16%) 0.0616
Diuretic 8 (5.03%) 129 (15.47%) 0.0005
Antiarrhythmic drug 12 (7.55%) 104 (12.47%) 0.0765
Data are numbers of individuals (%) unless otherwise stated. The item of other peripheral vascular disease is not presented because its number was zero.
Abbreviations: ARB angiotensin II receptor blocker, ACEI angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, NSAID non-steroidal anti-
inflammatory drug, H2 blocker histamine2-receptor antagonist.
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a relative risk of 2.61 (95% CI, 1.18 to 5.80; p = 0.0184)
for propensity adjustment and a relative risk of 2.06
(95% CI, 1.02 to 4.13; p = 0.043) for the multivariate
model, suggesting that the risk of GI bleeding was increased
in patients treated with the combination of clopidogrel and
aspirin. The risk of intracranial hemorrhage was not signifi-
cantly different between clopidogrel plus aspirin users and
aspirin alone users.
Discussion
In this study, we evaluated and compared the effects of
combination therapy of clopidogrel plus aspirin andaspirin monotherapy on laboratory parameters includ-
ing creatinine, AST, ALT, hemoglobin level, hematocrit,
WBC, RBC and PLT counts in a short-term administra-
tion period up to two months. We found that the re-
duction of WBC count in clopidogrel plus aspirin users
was significantly greater than that in aspirin alone
users. These results suggest that the hematological ad-
verse effect on leukocytes is greater with combination
therapy of clopidogrel plus aspirin than with aspirin
monotherapy.
A variety of hematological adverse reactions, including
leukopenia, agranulocytosis, and thrombocytopenia, have
been reported in patients receiving clopidogrel or aspirin
Table 2 Baseline laboratory parameters of studied patients
Laboratory test Clopidogrel plus aspirin (n = 159) Aspirin alone (n = 834) p
mean (95% CI) mean (95% CI)
Creatinine (mg/dl) 0.93 (0.72, 1.14) 1.12 (1.03, 1.22) 0.0853
ALT (U/L) 35.33 (33.15, 37.52) 36.47 (35.52, 37.42) 0.3490
AST (U/L) 35.14 (32.96, 37.32) 36.56 (35.61, 37.51) 0.2409
WBC (103/μL) 6.96 (6.30, 7.61) 6.99 (6.74, 7.25) 0.9210
RBC (106/μL) 4.16 (4.06, 4.270) 4.07 (4.02, 4.12) 0.1177
PLT (103/μL) 222.5 (205.3, 239.6) 239.9 (232.4, 247.4) 0.0675
Hemoglobin (g/dL) 13.14 (12.81, 13.47) 12.76 (12.61, 12.90) 0.0369
Hematocrit (%) 38.84 (37.89, 39.80) 37.87 (37.45, 38.29) 0.0664
Abbreviations: ALT alanine aminotransferase, AST asparate aminotransferase, WBC white blood cell count, RBC red blood cell count, PLT platelet count, CI
confidence interval.
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with a significant reduction in neutrophils were 0.10 per-
cent and 0.17 percent in the clopidogrel and aspirin
groups, respectively [24]. In this study, the decrease in
mean WBC count during the exposure period from
baseline was significant both in clopidogrel plus aspirin
users and in aspirin alone users (data are included in
Additional file 3). Our findings support these previous
studies suggesting that the use of these antiplatelet
agents may be associated with leukopenia. Furthermore,
our findings suggested the possibility that the addition
of clopidogrel to aspirin may enhance the adverse effect
of aspirin alone on WBC count, although the mechan-
ism of myelotoxicity of these antiplatelet agents is not
clear. Our study is expected to help physicians make
decisions on drug selection because the adverse effect
of an antiplatelet therapy on leukocytes may be of clin-
ical concern, especially for patients with borderline low
WBC count.
The nature of antiplatelet therapy involves an inherent
risk of bleeding complications. Some trials reported that
the addition of aspirin to clopidogrel increases the risk
of hemorrhage [6,11-13]. Our study showed that GI
bleeding occurred more frequently in patients receiving
clopidogrel plus aspirin than in patients receiving aspirin
alone. Although patients who had increased risk of
bleeding, including diagnosis of severe hepatic insuffi-
ciency, renal failure, current peptic ulceration or historyTable 3 Mean changes in laboratory test values during expos
Laboratory test Clopidogrel plus aspirin (n = 159
mean (95% CI)
Δ WBC (103/μL)
Unadjusted −1.65 (−2.099, -1.202)
Propensity adjustment −1.509 (−1.999, -1.018)
Multivariate model −1.832 (−2.317, -1.346)
Δ indicates mean change in laboratory test value during exposure period from base
WBC white blood cell count, CI confidence interval. *: p < 0.05 (aspirin plus clopidogof systemic bleeding, were excluded from the study
population, there was a possibility that some covariates
at baseline might impact on the results of hemorrhagic
events. For instance, the risk of GI bleeding is increased
by administration of NSAIDs, advanced age and liver
disease, but is reduced by administration of PPI and H2
blockers. In this study, we used two adjustment methods
to control for these potential confounding covariates,
and thereby found that the risk of GI bleeding was in-
creased with combination therapy of clopidogrel and as-
pirin compared with aspirin alone, with a relative risk
ranging from 2.06 with the multivariate model and 2.61
for propensity adjustment. Our results were similar to
the results of two large-scale randomized clinical trials
reporting that dual antiplatelet therapy with clopidogrel
and aspirin increased the risk of GI bleeding approxi-
mately 2-fold compared with aspirin alone [6,13].
Our study has several limitations. It was a retrospect-
ive observational study, which has some issues with
respect to the potential for selection bias and confound-
ing factors. However, these problems caused by non-
randomized data could be solved by combination with
robust statistics; for example, propensity score method
[21]. We used rigorous statistical methods to control for
potential confounding variables between clopidogrel plus
aspirin and aspirin alone users, including propensity ad-
justment and a multivariate regression model. However,
their ability to control for differences was limited toure period from baseline
) Aspirin alone (n = 834) p
mean (95% CI)
−0.455 (−0.651, -0.259) <0.0001*
−0.312 (−0.803, 0.179) 0.0008*
−0.435 (−0.634, 0.237) <0.0001*
line. Data that showed a significant difference are presented. Abbreviations:
rel vs aspirin alone).
Table 4 Prevalence of hemorrhagic events




Propensity adjustment Multivariate model
no. (%) Relative risk (95% CI) P Relative risk (95% CI) P
Intracranial hemorrhage 5 (3.14%) 17 (2.04%) 1.71 (0.99, 2.94) 0.0507 1.23 (0.76, 2.01) 0.4009
Gastrointestinal bleeding 5 (3.14%) 6 (0.72%) 2.61 (1.18, 5.80) 0.0184 2.06 (1.02, 4.13) 0.0430
Abbreviation: CI confidence interval.
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study was an investigation to compare the effects of
clopidogrel plus aspirin and aspirin alone on laboratory
tests focusing on a short-term administration period up
to two months, but was not a long-term study that ana-
lyzed longitudinal data, including repeated measures of
laboratory parameters. Whether the duration of treat-
ment (especially, long-term treatment) is associated with
the outcome is of interest because long-term mainten-
ance of dual therapy (for about one year) is reasonable
in patients with ST-elevation myocardial infarction
according to the ACC/AHA guidelines [1]. We will
examine this theme in our next study. Third, we did fix
the daily dosage in both treatment groups: clopidogrel
(75 mg per day) plus aspirin (100 mg per day) users and
aspirin alone users (100 mg per day), because these dos-
ages are typically widely used to initiate antiplatelet ther-
apy. This study was not designed to assess the effects of
clopidogrel and aspirin at each dosage, because it is diffi-
cult to determine whether or not pharmacodynamics is
dose-dependent in clinical settings. Furthermore, this
study was undertaken to compare the effects of
clopidogrel plus aspirin and aspirin alone on laboratory
test results in a Japanese population; the cohorts identi-
fied for the study included only Japanese patients. There
are genetic polymorphisms in several CYP450 enzymes
involved in the metabolism of clopidogrel, such as vari-
ants in CYP2C19, particularly CYP2C19*2, which are as-
sociated with variability in clopidogrel active metabolite
bioavailability, antiplatelet effects, and clinical outcomes
[28,29]. Because the frequency of genetic variability dif-
fers among ethnic groups, it cannot be concluded
whether the present findings can be extended to people
of other races. The findings of our study, based on a
non-randomized design, call for further studies, such as
similar analyses of larger international databases or ran-
domized clinical trials for confirmation.
Conclusion
Our study showed that the reduction of WBC count
in clopidogrel plus aspirin users was significantly
greater than that in aspirin alone users, and that the
combination of clopidogrel and aspirin increased the
risk of GI bleeding compared with aspirin alone. Our
findings suggest that hematological adverse effects are
greater with combination therapy of clopidogrel plusaspirin than with aspirin monotherapy, and support
the experience noted in clinical practice that the use
of dual antiplatelet therapy requires regular checks of
hematological parameters.
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